Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2024)

Black Diamond Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at -$888000.0 for Q3 2024.

  • For Q3 2024, Capital Expenditures changed N/A year-over-year to -$888000.0; the TTM value through Sep 2024 reached $142000.0, changed N/A, while the annual FY2023 figure was $33000.0, 82.81% down from the prior year.
  • Capital Expenditures reached -$888000.0 in Q3 2024 per BDTX's latest filing, down from $848000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $848000.0 in Q2 2021 to a low of -$888000.0 in Q3 2024.
  • Average Capital Expenditures over 3 years is $23666.7, with a median of $32500.0 recorded in 2020.
  • The largest YoY upside for Capital Expenditures was 7000.0% in 2020 against a maximum downside of 327.27% in 2020.
  • A 3-year view of Capital Expenditures shows it stood at $142000.0 in 2020, then soared by 497.18% to $848000.0 in 2021, then crashed by 204.72% to -$888000.0 in 2024.
  • Per Business Quant, the three most recent readings for BDTX's Capital Expenditures are -$888000.0 (Q3 2024), $848000.0 (Q2 2021), and $40000.0 (Q1 2021).